Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novaccess Global Inc (OP: XSNX )

0.0065 -0.0005 (-7.14%)
Streaming Delayed Price Updated: 2:36 PM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Novaccess Global Inc

< Previous 1 2 Next >
NovAccess Global Announces New License to Advance its Immunotherapy Platform
Via ACCESSWIRE
NovAccess Global Announces $10.7 Million Financing
Via ACCESSWIRE
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
Via ACCESSWIRE
NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform
Via ACCESSWIRE
NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day
Via ACCESSWIRE
NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division
Via ACCESSWIRE
NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements
Via ACCESSWIRE
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award
Via ACCESSWIRE
NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies
Via ACCESSWIRE
NovAccess Global to Present at World Orphan Drug Congress
Via ACCESSWIRE
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress
Via ACCESSWIRE
NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company’s Lead Scientist and President of its StemVax Therapeutics Division
Via ACCESSWIRE
NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate
Via ACCESSWIRE
NovAccess Global Appoints Healthcare IP Consultant Dr. Peter Weinstein to Scientific Advisory Board
Via ACCESSWIRE
NovAccess Global Announces Virtual Annual Shareholders' Meeting
Via ACCESSWIRE
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1
Via ACCESSWIRE
NovAccess Global Announces Fireside Chat with Board Member Perspectives
Via ACCESSWIRE
NovAccess Global Announces Fireside Chat Series for the Investment Community
Via ACCESSWIRE
NovAccess Global Announces Effectiveness of Form S-1 Registration Statement
Via ACCESSWIRE
NovAccess Global Announces Uplisting to OTCQB
Via ACCESSWIRE
CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
Via ACCESSWIRE
CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
This corrects the release that ran earlier today, replacing the name of the executive quoted in the press release and other minor edits. 
From NovAccess Global Inc.
Via AccessWire
Exposures Product Safety
NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
Via ACCESSWIRE
NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
Accelerating on the Path Toward Immunotherapy for Glioblastoma (Brain Cancer) 
From NovAccess Global Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
NovAccess Global CEO Dwain Irvin Featured on MoneyTV
CLEVELAND, OH / ACCESSWIRE / June 14, 2022 / NovAccess Global Inc. (OTC PINK:XSNX) announced that its Chief Executive Officer Dr. Dwain Irvin was a featured guest on MoneyTV, an... 
From NovAccess Global Inc.
Via AccessWire
Exposures Product Safety
This Week on MoneyTV with Donald Baillargeon, 6/10
HOLLYWOOD, CA / ACCESSWIRE / June 10, 2022 / Cancer treatment, metaverse, coping; this week on MoneyTV with Donald Baillargeon 
From MoneyTV
Via AccessWire
NovAccess Global to Participate in LD Micro Invitational XII Conference
CLEVELAND, OH / ACCESSWIRE / May 19, 2022 / NovAccess Global Inc. (OTC PINK:XSNX) announced that its Chief Executive Officer Dr. Dwain Irvin is scheduled to participate in the LD Micro Invitational XII... 
From NovAccess Global Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
NovAccess Global Stock Redemption and Expanded Board of Directors Reinforces Shareholder Value and Positions the Company to Accelerate Objectives
LOS ANGELES, CA / ACCESSWIRE / March 17, 2022 / NovAccess Global Inc. (OTC PINK:XSNX) announced today the closing of a series of transactions which results in the reduction of potential common stock... 
From NovAccess Global Inc.
Via AccessWire
NovAccess Global, Inc.'s CEO to attend BIO Conference in New York
CLEVELAND, OH / ACCESSWIRE / February 15, 2022 / NovAccess Global, Inc. (OTC PINK:XSNX) announced that its CEO Dr. Dwain Irvin to attend the BIO (Biotechnology innovation organization) CEO and investor... 
From NovAccess Global Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
NovAccess Global, Inc. Names Neil Laird, Chief Financial Officer
CLEVELAND, OH / ACCESSWIRE / December 8, 2021 / NovAccess Global, Inc. (OTC PINK:XSNX) welcomes new Chief Financial Officer (CFO), Neil Laird. "I am pleased to welcome Neil Laird to the management... 
From NovAccess Global Inc.
Via AccessWire
Topics Retirement
Exposures Pension
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.